2025
An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts.
Zeidan A, Griffiths E, Dinardo C, Mannis G, Montesinos P, Arnan M, Savona M, Odenike O, McCloskey J, Amin H, Fathi A, Bernal del Castillo T, Rodriguez-Macias G, Liesveld J, Im A, Oganesian A, Xu Q, Dijkstra M, Keer H, Roboz G. An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts. Journal Of Clinical Oncology 2025, 43: 6504-6504. DOI: 10.1200/jco.2025.43.16_suppl.6504.Peer-Reviewed Original ResearchAcute myeloid leukemiaAll-oral regimenInduction chemotherapyEuropean LeukemiaNetCR rateMedian time to CRTreatment-emergent adverse eventsBCL-2 inhibitor venetoclaxDiagnosed AMLDiagnosed acute myeloid leukemiaMedian CR durationPhase 2 partAll-oral regimensIntensive induction chemotherapyPhase 1/2 trialBone marrow examinationMedian Follow-UpTime to CRConfidence intervalsDrug-drug interactionsPhase 2 cohortIntravenous decitabineMedian OSCR durationFebrile neutropenia
2024
The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
Shivaram S, Yan H, Tang H, Anderson H, Kaddoura M, Wiedmeier-Nutor J, Tian S, Howe M, Bolarinwa A, Zepeda Mendoza C, Gupta V, Lehman S, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Maura F, Kumar S, Baughn L. The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma. Blood 2024, 144: 4635-4635. DOI: 10.1182/blood-2024-205385.Peer-Reviewed Original ResearchMayo Clinic cohortNoxa proteinMultiple myelomaG alleleIncreased expressionGene expressionCyclin D1Clinical cohortExpression of CCND1Cell linesAllele specific effectsBCL-2 inhibitor venetoclaxLevels of NoxaHistone mark H3K27acG risk allelePrimary cytogenetic abnormalityPlasma cell malignancyAssociated with increased expressionRNA sequencing dataHuman myeloma cell linesKO cell linesWestern blottingAnalyzed whole-exomeChIP-seqWhole genomeFinal Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
Stone R, DeAngelo D, Letai A, Galinsky I, Weiner H, Halpin A, Noyes L, Smith H, Lombardi C, Leonard R, Fell G, Flammand Y, Ryan J, Konopleva M, Wadleigh M, Stahl M, Chen E, Volpe V, Winer E, Garcia J, Luskin M, Patel A. Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia. Blood 2024, 144: 4261. DOI: 10.1182/blood-2024-203683.Peer-Reviewed Original ResearchMaximum tolerated doseAcute myeloid leukemiaMeasurable residual diseaseBCL-2 inhibitor venetoclaxAra-CExpansion cohortInhibitor venetoclaxANC recoverySeptic deathMyeloid leukemiaEscalation phaseDose levelsMRD negativityNegative measurable residual diseaseUntreated acute myeloid leukemiaRate of complete remissionUntreated adultsBcl-2High dose cytarabineTumor lysis syndromeInitiation of therapyPhase I studyAra-C doseCore binding factor rearrangementsCytarabine consolidationPhase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
Lane A, Garcia J, Raulston E, Garzon J, Galinsky I, Baxter E, Leonard R, DeAngelo D, Luskin M, Reilly C, Stahl M, Stone R, Vedula R, Wadleigh M, Winer E, Mughal T, Brooks C, Gupta I, Stevenson K, Neuberg D, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Advances 2024, 8: 591-602. PMID: 38052038, PMCID: PMC10837492, DOI: 10.1182/bloodadvances.2023011721.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAgent azacitidineMyelodysplastic syndromeMyeloid leukemiaTreatment of blastic plasmacytoid dendritic cell neoplasmHigh-risk acute myeloid leukemiaBlastic plasmacytoid dendritic cell neoplasmDNA hypomethylating agent azacitidineRecommended phase 2 doseHigh-risk myelodysplastic syndromeAdverse-risk acute myeloid leukaemiaBCL-2 inhibitor venetoclaxPlasmacytoid dendritic cell neoplasmInterleukin-3Bcl-2Median overall survivalPhase 1b studyProgression-free survivalPhase 1b trialHypomethylating agent azacitidineDendritic cell neoplasmAntiapoptotic molecule Bcl-2Recombinant interleukin-3Interleukin-3 receptorExpansion cohort
2023
Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting
Manzoor B, Huntington S, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi J. Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting. Blood 2023, 142: 5085. DOI: 10.1182/blood-2023-177939.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaPost-index periodU.S. Medicare beneficiariesBTK inhibitorsHealth care costsMedicare beneficiariesTreatment periodIndex dateMonth 13Months 0Prescription coverageLymphocytic leukemiaHealthcare costsCare costsMonths post-index periodDiagnosis of CLLMonthly health care costsMonthly costCause total costsFixed-duration treatmentPre-index periodPrior CLL treatmentTreatment-free remissionBCL-2 inhibitor venetoclaxFront-line setting
2021
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP, Zeidan AM. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon? Best Practice & Research Clinical Haematology 2021, 34: 101245. PMID: 33762100, DOI: 10.1016/j.beha.2021.101245.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHigh-risk myelodysplastic syndromeHMA failureMyelodysplastic syndromeAgent azacitidineSalvage therapyNovel immune checkpoint inhibitorsEffective salvage therapyBCL-2 inhibitor venetoclaxCommon clinical dilemmaManagement of patientsStandard of careRationale drug developmentCheckpoint inhibitorsFrontline therapyMost patientsComplete responseMDS patientsFrontline settingFrontline treatmentShorter survivalClinical dilemmaInhibitor venetoclaxClinical testingPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply